Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression

Teodóra Bánfalvi, K. Gilde, Mariann Boldizsár, T. Kremmer, Szabolcs Ottó

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Serum S-100 protein is widely used as a marker of melanoma and since 5- S-cysteinyldopa (5-S-CD) is a precursor of melanin its serum and urinary levels can reflect melanoma progression. In this study we examined the concentration changes of serum S-100 protein and 5-S-CD in 252 melanoma patients of different clinical stages. Serum samples were taken from 252 melanoma patients at 860 times, from June 1996 to July 1998. The serum S-100 protein was measured by the immunoluminometric assay, levels of 5S-CD was determined by HPLC. The value of S-100 protein in patients with primary melanoma (0.11 μg/l) and in patients without symptoms (0.15 μg/l) ranged around the normal level (0.01-0.12 μg/l). There was a significant difference between the values of patients with or without symptoms. There was a similarly significant difference between the S100 values of clinical Stage I (0.11 μg/l) and Stage III (2.91 μg/l) as well as between those of clinical Stage II (0.47 μg/l) and Stage III (2.91 μg/l), respectively. Analyzing the values of patients with symptoms we observed significant difference between the S-100 protein values of patients with primary tumor and those with solitary or multiple distant metastases. In case of 5-S-CD significant difference was found between clinical Stage I and III as well as clinical Stage II and III. Furthermore, there was a significant difference between the mean marker values of patients with primary tumor, lymph node, lung metastasis and clinical stage III.

Original languageEnglish
Pages (from-to)218-222
Number of pages5
JournalPathology and Oncology Research
Volume5
Issue number3
DOIs
Publication statusPublished - Sep 1999

Fingerprint

Cysteinyldopa
S100 Proteins
Protein S
Melanoma
Serum
Blood Proteins
Neoplasm Metastasis
Neoplasms
Lymph Nodes
High Pressure Liquid Chromatography

Keywords

  • 5-S-cysteinyldopa
  • Melanoma
  • S-100 protein

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. / Bánfalvi, Teodóra; Gilde, K.; Boldizsár, Mariann; Kremmer, T.; Ottó, Szabolcs.

In: Pathology and Oncology Research, Vol. 5, No. 3, 09.1999, p. 218-222.

Research output: Contribution to journalArticle

Bánfalvi, Teodóra ; Gilde, K. ; Boldizsár, Mariann ; Kremmer, T. ; Ottó, Szabolcs. / Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression. In: Pathology and Oncology Research. 1999 ; Vol. 5, No. 3. pp. 218-222.
@article{eef4ddffe743439b9439c5e206e74858,
title = "Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression",
abstract = "Serum S-100 protein is widely used as a marker of melanoma and since 5- S-cysteinyldopa (5-S-CD) is a precursor of melanin its serum and urinary levels can reflect melanoma progression. In this study we examined the concentration changes of serum S-100 protein and 5-S-CD in 252 melanoma patients of different clinical stages. Serum samples were taken from 252 melanoma patients at 860 times, from June 1996 to July 1998. The serum S-100 protein was measured by the immunoluminometric assay, levels of 5S-CD was determined by HPLC. The value of S-100 protein in patients with primary melanoma (0.11 μg/l) and in patients without symptoms (0.15 μg/l) ranged around the normal level (0.01-0.12 μg/l). There was a significant difference between the values of patients with or without symptoms. There was a similarly significant difference between the S100 values of clinical Stage I (0.11 μg/l) and Stage III (2.91 μg/l) as well as between those of clinical Stage II (0.47 μg/l) and Stage III (2.91 μg/l), respectively. Analyzing the values of patients with symptoms we observed significant difference between the S-100 protein values of patients with primary tumor and those with solitary or multiple distant metastases. In case of 5-S-CD significant difference was found between clinical Stage I and III as well as clinical Stage II and III. Furthermore, there was a significant difference between the mean marker values of patients with primary tumor, lymph node, lung metastasis and clinical stage III.",
keywords = "5-S-cysteinyldopa, Melanoma, S-100 protein",
author = "Teod{\'o}ra B{\'a}nfalvi and K. Gilde and Mariann Boldizs{\'a}r and T. Kremmer and Szabolcs Ott{\'o}",
year = "1999",
month = "9",
doi = "10.1053/paor.1999.0218",
language = "English",
volume = "5",
pages = "218--222",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression

AU - Bánfalvi, Teodóra

AU - Gilde, K.

AU - Boldizsár, Mariann

AU - Kremmer, T.

AU - Ottó, Szabolcs

PY - 1999/9

Y1 - 1999/9

N2 - Serum S-100 protein is widely used as a marker of melanoma and since 5- S-cysteinyldopa (5-S-CD) is a precursor of melanin its serum and urinary levels can reflect melanoma progression. In this study we examined the concentration changes of serum S-100 protein and 5-S-CD in 252 melanoma patients of different clinical stages. Serum samples were taken from 252 melanoma patients at 860 times, from June 1996 to July 1998. The serum S-100 protein was measured by the immunoluminometric assay, levels of 5S-CD was determined by HPLC. The value of S-100 protein in patients with primary melanoma (0.11 μg/l) and in patients without symptoms (0.15 μg/l) ranged around the normal level (0.01-0.12 μg/l). There was a significant difference between the values of patients with or without symptoms. There was a similarly significant difference between the S100 values of clinical Stage I (0.11 μg/l) and Stage III (2.91 μg/l) as well as between those of clinical Stage II (0.47 μg/l) and Stage III (2.91 μg/l), respectively. Analyzing the values of patients with symptoms we observed significant difference between the S-100 protein values of patients with primary tumor and those with solitary or multiple distant metastases. In case of 5-S-CD significant difference was found between clinical Stage I and III as well as clinical Stage II and III. Furthermore, there was a significant difference between the mean marker values of patients with primary tumor, lymph node, lung metastasis and clinical stage III.

AB - Serum S-100 protein is widely used as a marker of melanoma and since 5- S-cysteinyldopa (5-S-CD) is a precursor of melanin its serum and urinary levels can reflect melanoma progression. In this study we examined the concentration changes of serum S-100 protein and 5-S-CD in 252 melanoma patients of different clinical stages. Serum samples were taken from 252 melanoma patients at 860 times, from June 1996 to July 1998. The serum S-100 protein was measured by the immunoluminometric assay, levels of 5S-CD was determined by HPLC. The value of S-100 protein in patients with primary melanoma (0.11 μg/l) and in patients without symptoms (0.15 μg/l) ranged around the normal level (0.01-0.12 μg/l). There was a significant difference between the values of patients with or without symptoms. There was a similarly significant difference between the S100 values of clinical Stage I (0.11 μg/l) and Stage III (2.91 μg/l) as well as between those of clinical Stage II (0.47 μg/l) and Stage III (2.91 μg/l), respectively. Analyzing the values of patients with symptoms we observed significant difference between the S-100 protein values of patients with primary tumor and those with solitary or multiple distant metastases. In case of 5-S-CD significant difference was found between clinical Stage I and III as well as clinical Stage II and III. Furthermore, there was a significant difference between the mean marker values of patients with primary tumor, lymph node, lung metastasis and clinical stage III.

KW - 5-S-cysteinyldopa

KW - Melanoma

KW - S-100 protein

UR - http://www.scopus.com/inward/record.url?scp=0345363240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345363240&partnerID=8YFLogxK

U2 - 10.1053/paor.1999.0218

DO - 10.1053/paor.1999.0218

M3 - Article

C2 - 10491021

AN - SCOPUS:0345363240

VL - 5

SP - 218

EP - 222

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -